Keros Cutting 45% of Staff, Ending Development of Cibotercept in PAH

Dow Jones

May 29, 2025

By Colin Kellaher

Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH.

Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings.

The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year.

Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events.

Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it plans to provide a preliminary update on the review process by June 9.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 29, 2025 07:37 ET (11:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2539425203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539425203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539425203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539425203","market":"fut","top_or_hot":-1,"title":"Keros Cutting 45% of Staff, Ending Development of Cibotercept in PAH","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH. \n</p>\n<p>\n  Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings. \n</p>\n<p>\n  The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year. \n</p>\n<p>\n  Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events. \n</p>\n<p>\n  Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it plans to provide a preliminary update on the review process by June 9. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2025 07:37 ET (11:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keros Cutting 45% of Staff, Ending Development of Cibotercept in PAH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeros Cutting 45% of Staff, Ending Development of Cibotercept in PAH\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-29 19:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH. \n</p>\n<p>\n  Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings. \n</p>\n<p>\n  The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year. \n</p>\n<p>\n  Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events. \n</p>\n<p>\n  Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it plans to provide a preliminary update on the review process by June 9. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2025 07:37 ET (11:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2539425203","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539425203","pubTimestamp":1748518620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH.Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings.The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year.Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events.Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Keros裁员45%，终止Cibotercept治疗PAH的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product candidate in pulmonary arterial hypertension, or PAH. \n\n\n  Keros on Thursday said it will have 85 full-time employees after the job cuts, adding that it expects about $17 million in average annualized cost savings. \n\n\n  The Lexington, Mass., company said it expects to incur about $3.2 million in cash charges associated with the reorganization, which it expects to complete by the end of the year. \n\n\n  Keros late last year halted two treatment arms in a Phase 2 study of cibotercept in PAH based on the observation of pericardial effusions, and it stopped all dosing in the trial in January based on a safety review due to new observations of pericardial effusion adverse events. \n\n\n  Keros, which in April said it was reviewing alternatives aimed at maximizing shareholder value, including a possible sale, on Thursday said it plans to provide a preliminary update on the review process by June 9. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2025 07:37 ET (11:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}